SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing a volatile trading session following its WWDC keynote, as investors react to new Siri AI features and an artificial intelligence partnership with Google. While some traders are focused on a typical 'sell the news' price decline, the community is actively debating the company's competitive standing in the AI landscape compared to its peers.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending as investors digest a major 210 MW lease agreement at its Delta Forge 2 campus, a development that continues to drive optimism around the company's AI Factory franchise model and its ability to secure long-term revenue with hyperscalers. While the community remains highly bullish on the firm's expansion pace and infrastructure execution, recent price action has triggered intense debate between those treating current volatility as a strategic buying opportunity and others wary of broader sector valuation concerns.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant community attention as investors position for a highly anticipated 52-week data release from their VELA trials, with many speculating an imminent announcement could trigger a major revaluation or M&A activity. Market participants are intensely debating the timing of this data drop in relation to the company's scheduled investor conference appearances, while keeping a close eye on institutional block trading and potential short squeezes as the company progresses toward commercialization.

AmpliTech Group, Inc. engages in the design, development, and manufacture of radio frequency components. It offers signal processing components for satellite and 5G communications networks, defense, space, and other commercial applications. Its products include amplifiers, passive components, mechanical drawings, monolithic microwave integrated circuit, and 5G. The company was founded by Fawad Maqbool in 2002 and is headquartered in Hauppauge, NY.

Amplitech Group Inc

Amplitech Group is experiencing significant market attention driven by its recent FCC and Canadian ISED certifications, which clear the way for immediate commercial deployment of its 5G Native DAS solution. The community is actively discussing the stock's potential for a major rerating as the company transitions from a research-focused entity to an infrastructure player with a multi-million dollar backlog, while also monitoring potential catalysts from the expanding AI-RAN and satellite sectors.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is trending as investors rally ahead of the company's highly anticipated NYSE uplisting scheduled for June 10th. The community is focused on the potential for increased institutional inflows, while debates persist over market volatility, regulatory risks, and the company's strategic position as a leader in the U.S. medical cannabis market.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to a flurry of conflicting sentiment, including reports of aggressive shareholder outreach ahead of the upcoming board vote and active discussions surrounding the potential impact of pending proxy advisor recommendations. The community remains deeply divided, balancing high-conviction bullishness regarding the company's proprietary pipeline and vaccine assets against significant frustration over management's communication strategy and executive compensation proposals.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is experiencing significant downward pressure as investors rotate capital ahead of an anticipated major IPO, leading to heavy volatility and active discussions about whether this decline is a temporary consolidation or a sign of a deeper correction. Despite the price action, long-term investors remain focused on the company's aggressive infrastructure expansion and strategic position in the AI compute market, viewing current pullbacks as potential buying opportunities.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently trending due to the EMA's recommendation to approve its oral Wegovy pill in Europe, a milestone that positions the company to potentially lead the oral obesity treatment market in the region. Community discussion remains polarized, with many investors debating the impact of increasing competition from Eli Lilly's pipeline versus Novo Nordisk's established first-mover advantage and expanding global footprint.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is trending as investors react to clinical updates on its PRMT5 inhibitor program, balancing excitement over a new brain-penetrant candidate and upcoming combination trials with concerns regarding the discontinuation of earlier assets. The community is actively debating the company's long-term potential, with bulls citing a deep institutional pipeline and potential buyout value, while skeptics focus on the recent price volatility and the dilution risks associated with financing clinical milestones.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

Structure Therapeutics (GPCR) is trending following positive Phase 2 obesity trial data, which demonstrated strong, durable weight loss and a competitive tolerability profile, fueling significant investor interest and M&A speculation. Community discussions are heavily focused on the stock's best-in-class potential in the small-molecule GLP-1 space, comparing its growth prospects and takeout valuation potential against other obesity-focused biotech peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is TCNNF Stock Surging Today?

Equity

Trulieve Cannabis said it has completed a restructuring that moves its mixed-use cannabis assets into a separate entity, Harvest Enterprises.

AKAN Stock Leaves Cannabis Peers In The Smoke With A Stunning 1,700% Rally In April — What’s Fueling The Run?

The company’s primary cannabis asset remains its Gabriola Island cultivation site in British Columbia, where it operates under a hemp license.

Weedcoin Jumps In Minutes After Trump’s Marijuana Shake-Up Speculation Sparks Sector Frenzy

Cryptocurrency

Cannabis stocks and ETFs rallied sharply, with names like TLRY, GTBIF, TCNNF, and IIPR jumping 6% to over 20% in midday trade.

Tilray, Aurora Cannabis, Trulieve Pull Back After Trump Marijuana Order Rally Runs Out Of Steam

Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide, but is instead aimed at improving medical marijuana and cannabidiol research.


Trump Orders Federal Action to Accelerate Cannabis Research Access

President Trump directed federal agencies Thursday to complete the marijuana rescheduling process initiated under the previous administration, focusing the executive action on expanding medical research opportunities for cannabis and CBD compounds.The executive order instructs the attorney general to finalize the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act, a shift that administration officials characterized as removing bureaucratic obstacles to scientific study rather than addressing recreational use or criminal penalties.In a press ...

Trump Moves A Step Closer To Reclassifying Marijuana As A Less Dangerous Drug — A Breakout Moment For Weed Industry?

The cannabis industry is enjoying renewed momentum under Trump, whose administration has adopted a notably more accommodative approach toward the drug and its related products.

Tilray, IIPR, Trulieve, Other Cannabis Stocks Rally On Report Of Government Considering Adding CBD Treatment For Medicare Patients  

The development comes close on the heels of President Donald Trump highlighting the potential benefits of cannabidiol in senior healthcare. 

Tilray, Canopy Growth: Cannabis Stocks Lose High Premarket After Surge Triggered By Trump's Post

Major weed stocks rallied the previous day after President Donald Trump's post, which highlighted the potential benefits of using cannabidiol in senior healthcare.

Extremely Bullish Sentiment

Investors are buzzing as the first major U.S. plant-touching cannabis company prepares for its historic move to the NYSE on June 10th.

Traders are hailing the company as a sector titan, often calling it the premier sure-thing play for institutional entry over traditional cannabis ETFs.

Anticipation of massive volume and institutional buying has enthusiasts predicting a dramatic rally that could trap skeptical short sellers.

TCNNFTrulieve Cannabis

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TCNNF News